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Clinical whole-exome sequencing (WES) for identification of mutations leading to Mendelian disease has been offered to the medical
community since 2011. Clinically undiagnosed neurological disorders are the most frequent basis for test referral, and currently, approx-
imately 25% of such cases are diagnosed at the molecular level. To date, there are approximately 4,000 ‘‘known’’ disease-associated loci,
and many are associated with striking dysmorphic features, making genotype-phenotype correlations relatively straightforward. A
significant fraction of cases, however, lack characteristic dysmorphism or clinical pathognomonic traits and are dependent uponmolec-
ular tests for definitive diagnoses. Further, many molecular diagnoses are guided by recent gene-disease association discoveries. Hence,
there is a critical interplay between clinical testing and research leading to gene-disease association discovery. Here, we describe four pro-
bands, all of whom presented with hypotonia, intellectual disability, global developmental delay, andmildly dysmorphic facial features.
Three of the four also had sleep apnea. Each was a simplex case without a remarkable family history. UsingWES, we identified AHDC1 de
novo truncating mutations that most likely cause this genetic syndrome.De novo pathogenic mutations are a major cause of spo-
radic human genetic disease.1,2 Whole-exome sequencing
(WES)3 using next-generation-sequencing methods has
proven to be a powerful tool for molecular diagnosis of
mutations in genes known to underlie Mendelian dis-
ease,1 as well as for the discovery of novel disease-associ-
ated loci.4 Despite the rapid development of these new
molecular tools, the majority of individuals who are sus-
pected to have a genetic disease remain undiagnosed. In
part, this reflects the incomplete status of the catalog of
characterized Mendelian-disease-associated genes; this cat-
alog currently includes about 4,000 entries and represents
less than one-quarter of the annotated genes (~21,000) in
the human genome.
We appliedWES to identify de novo genetic changes in a
parent-offspring trio in which the proband exhibited devel-
opmental delay, hypotonia, mild dysmorphic features,
sleep apnea, and other symptoms (Figure 1; Table 1; Table
S1, available online). A truncating de novo mutant allele
was found in AT-hook, DNA-binding motif, containing 1
(AHDC1 [RefSeq accession number NM_001029882.2]).
We subsequently identified an additional three indepen-
dent simplex cases with similar phenotypes and de novo
truncating events in the same gene. This pattern of de
novo variation in AHDC1 is highly unlikely to have
occurred by chance andmost likely represents the underly-
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lated parents) who presented with hypotonia, delayed
motor milestones, dysmorphic features, hepatomegaly,
and laryngomalacia (Figure 2). Both the healthy parents
and the proband were analyzed by WES.1 Informed con-
sent was obtained, and all procedures were followed in
accordance with the ethical standards prescribed and
approved by the Baylor College of Medicine Institutional
Review Board. The DNA from each of the three samples
was sequenced at an average depth of coverage of greater
than 120-fold, and greater than 95% of the targeted bases
were covered at 20-fold or higher. The results identified
de novo events, including single-nucleotide variants
(SNVs) or small indel mutations in the proband, in five
genes: c.415G>A (p.Glu139Lys) in CALY (MIM 604647;
RefSeq NM_015722.3), c.1429G>A (p.Gly477Arg) in
PTPRB (MIM 176882; RefSeq NM_001109754.2),
c.1076C>A (p.Ala359Glu) in TBCK (RefSeq
NM_033115.4), c.1093dup (p.Met365Asnfs*4) in
CCDC66 (RefSeq NM_001141947.1), and c.2373_2374
delTG (p.Cys791Trpfs*57) in AHDC1; all sequence coordi-
nates are based on human reference genome hg19 (UCSC
Genome Browser). A comparison of the minor allele fre-
quencies between these variants and similar mutations in
the NHLBI Exome Sequencing Project Exome Variant
Server (EVS) and a local variant database (see below) elimi-
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Figure 1. Pedigrees and Mutations of Four Affected Familiesframeshift mutation as likely disease-causing candidates
because of their occurrence in individuals without
suspected developmental disorders. The remaining
variant, the de novo deletion mutation in AHDC1
(c.2373_2374delTG), results in a frameshift of the
AHDC1 open reading frame, beginning at codon 791,
and by conceptual translation is predicted to cause a pre-Table 1. Major Clinical Features of Four Probands
Subject
1 2
Gender female female
Age 18 months 4 years
Ethnicity European descent South Asian
Intellectual disability NA moderate
Speech delay no words at 18 months
of age
two words at 4 years
of age
Motor delay no sitting at 18 months
of age
sitting at 19 months
of age, walking at
24 months of age
Hypotonia and
failure to thrive
yes yes
Dysmorphic facial
features
low-set ears, esotropia,
upslanting palpebral
fissures, micrognathia,
flat nasal bridge
protuberant ears,
upslanting palpebral
fissures, flat nasal
bridge
Anatomic
upper-airway
obstruction
laryngomalacia,
obstructive
sleep apnea
obstructive sleep apnea
Family history negative, one healthy
sibling
negative
Previous testing MD, SMA, PWS, CMA,
metabolic work-up
FX, CMA (18 Mb AOH
on chromosome 5),
metabolic work-up
See Table S1 for additional details of clinical presentations. Abbreviations are as foll
ile X chromosome; MD, myotonic dystrophy; NA, not available; PWS, Prader-Wil
The Ammature termination codon (p.Cys791Trpfs*57). Predicted
truncating mutations in AHDC1 are absent from the
1000 Genomes database (healthy individuals), the EVS
(about 6,500 individuals), and a database of exome data
from the Atherosclerosis Risk in Communities study
(approximately 8,000 community-based individuals). The
absence of truncating mutations in AHDC1 in these
databases suggests that such gene perturbations are not
consistent with general good health, and therefore the
observed AHDC1 mutation was considered likely to be
pathogenic.
We next screened 2,000 entries of clinical WES data at
the Whole Genome Laboratory at Baylor College of
Medicine to identify possible additional AHDC1 muta-
tions. Those data consist primarily of individuals who
had a sample submitted by their physician for clinical
WES, as previously described.1 The clinical WES test
focuses on exome sequencing of the proband, and com-
plete parental WES data are not routinely generated.
Among 2,000 previously tested individuals, of whom
1,700 had developmental delay and/or intellectual dis-
abilities, three were found to harbor frameshift alleles in
AHDC1 (c.2898delC [p.Tyr967Thrfs*175] at chr1:
27,875,729, c.2373_2374delTG [p.Cys791Trpfs*57] at
chr1: 27,876,253–27,876,254, and c.2547delC [p.Ser850
Profs*82] at chr1: 27,876,080; Figures 1 and 3). The3 4
male male
8 years 11 years
European descent European descent
mild moderate to severe
first words after 1 year of age,
persistent speech therapy
no words, noncommunicating
autism
sitting at 9 months of age,
walking at 18 months of age
sitting at 15 months of age,
no independent ambulation
yes yes
protuberant low-set ears, small
earlobes, hypertelorism,
downslanting palpebral fissures,
mild ptosis, micrognathia
upturned earlobes,
hypertelorism, esotropia,
flat nasal bridge
laryngomalacia, obstructive
sleep apnea
suspected tracheomalacia in
infancy, history of snoring
negative, one healthy sibling negative, two healthy siblings
CMA, FX, metabolic work-up SMA, PWS, CMA, metabolic
work-up
ows: AOH, absence of heterozygosity; CMA, chromosome microarray; FX, frag-
li syndrome; and SMA, spinal muscular atrophy.
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Figure 2. Facial Features of Probands
(A) Subject 1 (17months old) with a round face, full cheeks, horizontal eyebrows, a depressed nasal bridge, anteverted nares, hypoplastic
alae nasi, tented upper-lip vermillion, and microstomia.
(B) Subject 2 (4 years old) with thin eyebrows, a depressed nasal bridge, a bulbous nasal tip, and protuberant ears.
(C) Subject 3 (8 years old) with horizontal eyebrows, low-set ears, simple earlobes, and micrognathia.
(D) Subject 4 (21 months old) with a round face, full cheeks, horizontal eyebrows, a depressed nasal bridge, anteverted nares, tented
upper-lip vermillion, and microstomia.
(E and F) Front (E) and side (F) views of subject 4 (9 years old) with a round face, full cheeks, horizontal eyebrows, an acute nasal angle,
and fleshy pinna.mutations in the three individuals were further demon-
strated by PCR and Sanger DNA sequencing to be absent
in maternal and paternal DNA and were therefore inter-
preted as de novo events. Interestingly, subjects 1 and 3
had the same de novo mutation (c.2373_2374delTG
[p.Cys791Trpfs*57]). Except for the AHDC1 mutations,
we did not find other molecular events that could poten-
tially explain the conditions in these probands. Therefore,
the de novo mutations observed here in AHDC1 are the
most likely causes of the disease.
Clinical review of the four probands with AHCD1 trun-
cating mutations revealed that all had a history of congen-
ital hypotonia and failure to thrive (Table 1; Table S1). The
developmental histories were all remarkable for delayed
speech, especially expressive language. All had mildly
dysmorphic facial features that could be seen at a young
age, and those of subject 4 persisted at an older age. Three
probands also had a history of obstructive sleep apnea,
potentially because of upper-airway structural abnormal-786 The American Journal of Human Genetics 94, 784–789, May 1, 2ities. All probands had prior brain MRI demonstrating
hypoplasia of the corpus callosum. Simplification of the
gyral pattern and delayed myelination were also observed.
A retrocerebellar cyst was present in two of the four sub-
jects (Figure S1).
The independent occurrence of four de novo mutational
events at this locus in individuals with similar phenotypes
is highly unlikely5 (discussed in Bainbridge et al.6) and can
be asserted as extremely strong evidence that these muta-
tions in ACHD1 cause this simplex disorder. To the best
of our knowledge, the overall clinical presentations of
these probands do not precisely match any previously
known disease and, together with the statistical and
molecular data, suggest a genetic syndrome defined by
the mutations in AHDC1.
In subject 4, we also identified a de novo missense
change, c.2006A>C (p.Asp669Ala), in ANKRD11 (MIM
611192; RefSeq NM_013275.5). Haploinsufficiency of
ANKRD11 has been associated with KBG syndrome (MIM014
AB
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Figure 3. AHDC1 Genomic Organization
(A) Chromosomal location of AHDC1 and the genomic region surrounding it.
(B and C) Organization of AHDC1 (B) and the AT-hook DNA-binding region, conserved regions, and location of the three different trun-
cating alterations in the disorder (C). The histogram shows evolutionary conservation (see Figure S3 for details).148050), characterized by macrodontia, variable facial
dysmorphic features, mild skeletal anomalies, seizures in
some individuals, and mild to moderate intellectual
disability. However, the proband reported here did not
have macrodontia, skeletal defects, or other features of
KGB phenotypes and therefore did not meet the KBG diag-
nostic criteria proposed by Skjei et al.7 Additionally, the
well-characterized pathogenic mutations in ANKRD11 are
truncating.8 Thus, the significance of ANKRD11 missense
variant c.2006A>C (p.Asp669Ala) is unclear.
AHDC1 is located on the short arm of chromosome 1
within the cytogenetic band 1p36.11, but it is more
proximal than the regions identified from partial or com-
plete monosomy of 1p36,9 other small interstitial dele-
tions,10,11 and the nearby ARID1A, mutations in which
cause autosomal-dominant Coffin-Siris syndrome12 (MIM
135900). In the RefSeq and CCDS databases, the structural
organization of AHDC1 includes five untranslated exons
upstream of a single 4,929 bp coding exon followed by a
single downstream exon. This intronless coding structure
is a common feature for newly evolved genes created by
RNA-based retroposition.13 Indeed, orthologs of AHDC1
can only be found in vertebrate animals. Gaining intronThe Amstructures during evolution is correlated with higher
expression levels.14 The expression level and patterns of
AHDC1 are more similar to those of the multi-intron
ARID1A than to those of the intronless FOXG1 (MIM
164874), two other genes associated with severe develop-
mental disorders in humans (Figure S2). Therefore, it can
be postulated that the introns of the UTRs of AHDC1 affect
and/or enhance the expression levels in various human
tissues. On the nucleotide level, the single coding exon
of AHDC1 is well conserved among vertebrates (Figure 3).
The 30 untranslated exon also shows conservation levels
similar to those of the coding region, suggesting a potential
functional significance of this exon.
Human AHDC1 encodes a protein of 1,603 amino acids.
By aligning human AHDC1 against the protein sequences
of AHDC1 orthologs in mouse, zebrafish, and western
clawed frog, we found that the conserved amino acids
are clustered into two regions (Figure 3C; Figure S3), sug-
gesting two functional units. AHDC1 has two AT-hook
DNA-binding motifs located at codons 396–408 and 544–
556, contained in conserved region 1. AT-hook domains
are DNA-binding motifs that act to fasten proteins to AT-
rich sequences in DNA.15 Although conserved, region 2erican Journal of Human Genetics 94, 784–789, May 1, 2014 787
contains no known functional domains. In vitro protein-
interaction assays have shown that AHDC1 interacts
with a number of other nuclear proteins.16–21 Therefore,
conserved regions 1 and 2 of AHDC1 might interact with
the DNA elements or protein partners. Interestingly, all
of the de novo mutations found in these four probands
might truncate conserved region 2 but preserve region 1.
Given that each mutation identified here occurs in a single
coding exon, the modified mRNA might escape nonsense-
mediated decay,22 suggesting that the autosomal-domi-
nant mode of inheritance of these mutations is possibly
due to the formation of dominant-negative proteins rather
than haploinsufficiency.
Future research to better delineate the functional do-
mains of AHDC1 is now enhanced by the phenotypic asso-
ciation with the truncating mutations reported here. Also,
the phenotypes of the four probands are clearly similar in
retrospect. However, speech delay and obstructive sleep
apnea are sufficiently common conditions that it is un-
likely that this syndrome would have been identified if
the de novo mutations had not been uncovered first.
Supplemental Data
Supplemental Data include three figures and one table and can be
found with this article online at http://dx.doi.org/10.1016/j.ajhg.
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